Jacopo Pigozzo

Padova, 35128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Melanomas confined to the lung: Integrated clinicopathological and molecular assessment of a case series.

Melanomas confined to the lung: Integrated clinicopathological and molecular assessment of a case series.

Journal: Annals of diagnostic pathology

Published: August 03, 2026

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Journal: Cancers

Published: May 04, 2026

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.

Journal: Cancers

Published: April 16, 2026

Clinicopathologic Features and Treatment Outcomes of Squamoid Eccrine Ductal Carcinoma: A Comprehensive Retrospective Series.

Clinicopathologic Features and Treatment Outcomes of Squamoid Eccrine Ductal Carcinoma: A Comprehensive Retrospective Series.

Journal: The American Journal of dermatopathology

Published: April 15, 2026

Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma.

Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma.

Journal: Cancers

Published: April 14, 2026

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

Journal: Cancers

Published: April 14, 2026

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2025

Nivolumab for Resected Stage III or IV Melanoma at 9 Years.

Nivolumab for Resected Stage III or IV Melanoma at 9 Years.

Journal: The New England journal of medicine

Published: October 22, 2025

Immunohistochemical and molecular profiling of uveal melanoma: clinicopathological correlations from an Italian cohort.

Immunohistochemical and molecular profiling of uveal melanoma: clinicopathological correlations from an Italian cohort.

Journal: Pathologica

Published: September 10, 2025

Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.

Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 31, 2025

Identifying high-risk features and improving follow-up strategies in thin melanoma: a retrospective cohort study.

Identifying high-risk features and improving follow-up strategies in thin melanoma: a retrospective cohort study.

Journal: Clinical and experimental dermatology

Published: December 17, 2024

Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro.

Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro.

Journal: Frontiers in pharmacology

Published: November 26, 2024

Showing 1-12 of 63

Last Updated: 09/26/2026